News

  • 6 October 2011

    Santaris to report miravirsen drug trial results

    Santaris Pharma is set to release new clinical data results from the Phase 2a study of miravirsen, the microRNA-targeted drug designed to treat Hepatitis C virus (HCV) infected patients.

  • 5 October 2011

    Novavax RSV vaccine Phase 1 trial shows efficacy

    A Phase I clinical study conducted by Novavax has demonstrated positive top-line results of its respiratory syncytial virus (RSV) fusion (F) recombinant nanoparticle vaccine candidate.

  • 4 October 2011

    Baxter seeks European approval for HyQ

    Baxter International has submitted an application to the European Medicines Agency's Committee for Human Medicinal Products seeking marketing authorisation for HyQ, the company's investigational immunoglobulin (IG) therapy for use in...

  • 3 October 2011

    Horizon submits NDA for RA drug

    Horizon Pharma has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for Lodotra, for the treatment of rheumatoid arthritis.

  • 3 October 2011

    COG, Apeiron to jointly conduct APN301 trial

    Children's Oncology Group (COG) and Apeiron Biologics AG (Apeiron) will collaborate to evaluate Apeiron's APN301 in a clinical phase II study in pediatric neuroblastoma patients.

  • 2 October 2011

    Lannett Loxapine capsules get FDA approval

    The US Food and Drug Administration (FDA) has approved Lannett's abbreviated new drug application (ANDA) of Loxapine Capsules in 5mg, 10mg, 25mg and 50mg doses.

Go Top